Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 1/20 | 0.36 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.36 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18239658 | 0.82 | HTR2A (0.48) | PER2CRY1CRY2KDM4EMAPT | |
| SCHEMBL19960987 | 0.72 | HTR2A (0.42) | PER2KDM4EMAPTHTR2AHTR2C | |
| SCHEMBL23944980 | 0.70 | JAK3 (0.41) | KDM4EMAPTPTGDR2PTGDRTBXA2R | |
| SCHEMBL23944979 | 0.67 | PTGDR2 (0.33) | PTGDR2PTGDRTBXA2R | |
| SCHEMBL19960980 | 0.66 | HTR2A (0.36) | KDM4EMAPTHTR2AHTR2C | |
| SCHEMBL23944981 | 0.66 | CHRM2 (0.30) | — | |
| SCHEMBL19960979 | 0.65 | HTR2A (0.38) | PER2KDM4EMAPTHTR2AHTR2C | |
| SCHEMBL19960988 | 0.63 | PER2 (0.40) | PER2CRY1CRY2KDM4EMAPT | |
| SCHEMBL19960977 | 0.61 | HTR2A (0.35) | PER2CRY1CRY2KDM4EMAPT | |
| SCHEMBL18239660 | 0.61 | HTR2A (0.50) | KDM4EMAPTPTGDR2PTGDRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | PER2 4118/4885CRY1 4660/4885CRY2 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.